Improving quality of life for melanoma patients using a mobile coaching system
Pilot Study of the eHealth Application 'Cancer Patients Better Life Experience'
NA · The Netherlands Cancer Institute · NCT05827289
This study is testing if a mobile coaching app and smartwatch can help melanoma patients feel less tired and improve their quality of life while they receive immunotherapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Netherlands Cancer Institute (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Amsterdam, North Holland) |
| Trial ID | NCT05827289 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the impact of a patient-centered mobile coaching and monitoring system, known as CAPABLE, on the health-related quality of life, particularly fatigue, in melanoma patients undergoing immunotherapy. Participants will use the CAPABLE smartphone application and a multi-sensorial smartwatch for a period of three to six months. Their experiences and fatigue levels will be assessed through questionnaires at baseline, three months, and six months, and results will be compared to a historical cohort receiving standard care. The goal is to determine if the CAPABLE system can significantly reduce fatigue compared to usual treatment.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with histologically confirmed stage III or IV melanoma receiving immune checkpoint inhibitors.
Not a fit: Patients who are currently involved in another clinical trial or have been on active treatment for more than 12 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved management of fatigue and overall quality of life for melanoma patients undergoing immunotherapy.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in using technology to enhance patient care and quality of life.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years of age * Sufficient understanding of the Dutch language * Participants or their caregiver can use a smartphone (upon patient's consent) * Histologically confirmed stage III or IV melanoma who receive treatment with immune checkpoint-inhibitors, according to the clinical guidelines. Exclusion Criteria: * Included in a clinical trial * \>12 months on active treatment
Where this trial is running
Amsterdam, North Holland
- Netherlands Cancer Institute — Amsterdam, North Holland, Netherlands (RECRUITING)
Study contacts
- Study coordinator: Itske Fraterman, MSc
- Email: i.fraterman@nki.nl
- Phone: +31205122036
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Melanoma